Vertex Pharmaceuticals (VRTX) Short term Debt (2016)
Historic Short term Debt for Vertex Pharmaceuticals (VRTX) over the last 6 years, with Q4 2016 value amounting to $300.0 million.
- Vertex Pharmaceuticals' Short term Debt rose 32078.1% to $300.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $300.0 million, marking a year-over-year increase of 32078.1%. This contributed to the annual value of $300.0 million for FY2016, which is 32078.1% up from last year.
- Latest data reveals that Vertex Pharmaceuticals reported Short term Debt of $300.0 million as of Q4 2016, which was up 32078.1% from $297.8 million recorded in Q3 2016.
- Vertex Pharmaceuticals' Short term Debt's 5-year high stood at $300.0 million during Q4 2016, with a 5-year trough of $14.2 million in Q4 2014.
- In the last 3 years, Vertex Pharmaceuticals' Short term Debt had a median value of $108.8 million in 2015 and averaged $140.3 million.
- Examining YoY changes over the last 5 years, Vertex Pharmaceuticals' Short term Debt showed a top increase of 41681.94% in 2016 and a maximum decrease of 32078.1% in 2016.
- Over the past 3 years, Vertex Pharmaceuticals' Short term Debt (Quarter) stood at $14.2 million in 2014, then soared by 401.87% to $71.3 million in 2015, then surged by 320.78% to $300.0 million in 2016.
- Its Short term Debt was $300.0 million in Q4 2016, compared to $297.8 million in Q3 2016 and $221.6 million in Q2 2016.